Hangzhou Tangji Medical Technology Co., Ltd. has filed its IPO prospectus with the Hong Kong Stock Exchange, targeting a main board listing to capitalize on its position as China’s pioneer in endoscopic obesity treatment. The company’s flagship Gastric Bypass Stent System (GBS), first approved by NMPA in January 2024 as a Class III innovative medical device, offers a minimally invasive alternative to bariatric surgery for weight loss and metabolic disease management.
Forward‑Looking Statements This brief contains forward‑looking statements regarding Tangji Medtech’s Hong Kong IPO pricing and timing, GBS commercial adoption in Chinese hospitals, and endoscopic bariatric device market expansion. Actual results may differ due to HKEX listing approval delays, reimbursement negotiation outcomes with NMPA/NRDL, and competitive entry from global device manufacturers.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
